Symbols

BHC

Bausch Health·NYSE

--(--)

BHC fundamentals

BHC Q4 2025 Earnings

Bausch Health (BHC) released its earnings on Feb 18, 2026: revenue was 2.77B (YoY +9.95%), beat estimates; EPS was 1.0686 (YoY -5.15%), missed estimates.

Revenue / YoY

2.77B

+9.95%

EPS / YoY

1.0686

-5.15%

Report date

Feb 18, 2026

BHC Earnings Call Summary for Q4,2025

Record Growth: 11 straight quarters of revenue and EBITDA growth, with Q4 2025 revenue up 9% YoY to $1.391 billion.
Strategic Acquisitions: Shibo acquisition in China and Larsucosterol Phase III trial advance medical aesthetics and R&D pipelines.
Financial Strength: $1 billion+ operating cash flow, $320 million debt reduction in Q4, and 2026 guidance for 3-4% growth.
Xifaxan Outlook: 2026 peak year with 2027 EBITDA decline offset by Solta and International segment growth.
Bausch + Lomb Strategy: Patient approach to separation, focusing on B+L value creation through pipeline execution.

Earnings

EPS

Revenue

Revenue & Expenses

BHC has released its 2025 Q4 earnings report, with revenue of 2.80B, reflecting a YoY change of 9.26%, and net profit of -103.00M, showing a YoY change of -205.10%. The Sankey diagram below clearly presents BHC's revenue sources and cost distribution.

Key Indicators

Bausch Health (BHC) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Bausch Health (BHC)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Bausch Health (BHC)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Bausch Health (BHC)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown